DOCSLIB.ORG

Download Report Appendixes [PDF · 3.8

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Report Appendixes [PDF · 3.8 Appendices Appendix A: Search Strategies Main Search, MEDLINE (1966 to August Week 3 2008) 1. exp Hydroxymethylglutaryl-CoA 26. (cholestyramine or colestyramin$ or Reductase Inhibitors/ quantalan or questran or 2. Heptanoic Acids/ colesevelam).tw. 3. (Statin$ or reductase inhibitor$).tw. 27. Cholestyramine/ 4. (Simvastatin or Atorvastatin or 28. Colestipol/ Rosuvastatin or Pravastatin or Lovastatin 29. (colestimide or colestilan or or Fluvastatin or Mevastatin or colestipol).tw. Pitavastatin).mp. 30. or/25-29 5. (110862-48-1 or 287714-41-4 or 31. ezetimibe.mp. 75330-75-5 or 79902-63-9 or 81093-37- 32. 163222-33-1.rn. 0 or 93957-54-1).rn. 33. (cholester$ adj3 inhibit$).tw. 6. or/1-5 34. or/31-33 7. exp fatty acids, omega-3/ 35. (fibrate$ or fibric acid$).tw. 8. fatty acids, essential/ 36. Clofibric acid/ 9. Dietary Fats, Unsaturated/ 37. Clofibrate/ 10. linolenic acids/ 38. Bezafibrate/ 11. exp fish oils/ 39. Gemfibrozil/ 12. (n 3 fatty acid$ or omega 3).tw. 40. Procetofen/ 13. eicosapenta?noic.tw,hw,rw. 41. (gemfibrozil or fenofibrate or 14. docosahexa?noic.tw,hw,rw. bezafibrate or clofibrate or clofibric acid 15. alpha linolenic.tw,hw,rw. or procetofen or ciprofibrate).tw. 16. (linolenate or cervonic or 42. (637-07-0 or 25812-30-0 or 41859- timnodonic).tw,hw,rw. 67-0 or 882-09-7 or 49562-28-9).rn. 17. (mediterranean adj diet$).tw. 43. or/35-42 18. ((flax or flaxseed or flax seed or 44. niacin/ linseed or rape seed or rapeseed or 45. nicotinic acid/ canola or soy or soybean or walnut or 46. niacin.tw. mustard seed) adj2 oil$).tw. 47. or/44-46 19. (walnut$ or butternut$ or soybean$ 48. (Zetia or Lopid or Tricor or Lofibra or pumpkin seed$).tw. or Welchol or Colestid or Questran or 20. (fish adj2 oil$).tw. Prevalite).mp. 21. (cod liver oil$ or marine oil$ or 49. Drug Therapy, Combination/ marine fat$).tw. 50. (combination adj3 therapy).tw. 22. (salmon or mackerel or herring or 51. add-on therapy.tw. tuna or halibut or seal or seaweed or 52. or/49-51 anchov$).tw. 53. 6 and (or/24,30,34,43,47-48,52) 23. (fish consumption or fish intake or 54. clinical trial.pt. (fish adj2 diet$)).tw. 55. clinical trials/ 24. or/7-23 56. (randomized or randomly or 25. (anticholesteremic resin$ or (bile placebo).ab. adj3 resin$) or BAR or BAS or 57. trial.ti. Sequestrant$ or Bile acid$).tw. 58. randomized controlled trial.pt. 59. or/54-58 A-1 60. 53 and 59 66. limit 64 to meta analysis 61. or/24,30,34,43,47-48,52 67. or/60,65-66 62. exp Cardiovascular Diseases/ 68. limit 67 to (english language and 63. 61 and 62 yr="1980 - 2007") 64. or/6,63 69. remove duplicates from 68 65. limit 64 to systematic reviews Main Search, Embase (1980 to 2008 Week 36) 1. exp Hydroxymethylglutaryl 24. (anticholesteremic resin$ or (bile Coenzyme a Reductase Inhibitor/ adj3 resin$) or BAR or BAS or 2. (Statin$ or reductase inhibitor$).tw. Sequestrant$ or Bile acid$).tw. 3. (Simvastatin or Atorvastatin or 25. (cholestyramine or colestyramin$ or Rosuvastatin or Pravastatin or Lovastatin quantalan or questran or or Fluvastatin or Mevastatin or colesevelam).tw. Pitavastatin).mp. 26. Cholestyramine/ 4. (110862-48-1 or 287714-41-4 or 27. Colestipol/ 75330-75-5 or 79902-63-9 or 81093-37- 28. Colestyramine/ 0 or 93957-54-1).rn. 29. Colestilan/ 5. or/1-4 30. (colestimide or colestilan or 6. Omega 3 Fatty Acid/ colestipol).tw. 7. exp Essential Fatty Acid/ 31. or/23-30 8. exp Unsaturated Fatty Acid/ 32. Ezetimibe/ 9. Fish oils/ 33. ezetimibe.mp. 10. (n 3 fatty acid$ or omega 3).tw. 34. 163222-33-1.rn. 11. eicosapenta?noic.tw,hw,rw. 35. or/32-34 12. docosahexa?noic.tw,hw,rw. 36. Fibric Acid Derivative/ 13. alpha linolenic.tw,hw,rw. 37. (fibrate$ or fibric acid$).tw. 14. (linolenate or cervonic or 38. Clofibric acid/ timnodonic).tw,hw,rw. 39. Clofibrate/ 15. (mediterranean adj diet$).tw. 40. Bezafibrate/ 16. ((flax or flaxseed or flax seed or 41. Gemfibrozil/ linseed or rape seed or rapeseed or 42. Procetofen/ canola or soy or soybean or walnut or 43. (gemfibrozil or fenofibrate or mustard seed) adj2 oil$).tw. bezafibrate or clofibrate or clofibric acid 17. (walnut$ or butternut$ or soybean$ or procetofen or ciprofibrate).tw. or pumpkin seed$).tw. 44. (637-07-0 or 25812-30-0 or 41859- 18. (fish adj2 oil$).tw. 67-0 or 882-09-7 or 49562-28-9).rn. 19. (cod liver oil$ or marine oil$ or 45. or/36-44 marine fat$).tw. 46. nicotinic acid/ 20. (salmon or mackerel or herring or 47. niacin.tw. tuna or halibut or seal or seaweed or 48. or/46-47 anchov$).tw. 49. (Zetia or Lopid or Tricor or Lofibra 21. (fish consumption or fish intake or or Welchol or Colestid or Questran or (fish adj2 diet$)).tw. Prevalite).mp. 22. or/6-21 50. Drug Therapy, Combination/ 23. Bile Acid Sequestrant/ 51. (combination adj3 therapy).tw. A-2 52. add-on therapy.tw. 60. 54 and 59 53. or/50-52 61. or/22,31,35,45,48-49,53 54. 5 and (or/22,31,35,45,48-49,53) 62. exp Cardiovascular Disease/ 55. limit 54 to "treatment (2 or more 63. 61 and 62 terms high specificity)" 64. 5 or 63 56. clinical trials/ 65. limit 64 to "reviews (2 or more terms 57. (randomized or randomly or high specificity)" placebo).ab. 66. or/60,65 58. trial.ti. 67. limit 66 to (english language and 59. or/55-58 yr="1980 - 2007") Main Search, CENTRAL (The Cochrane Library, Issue 3, 2008) 1. exp Hydroxymethylglutaryl 20. (salmon or mackerel or herring or Coenzyme a Reductase Inhibitor/ tuna or halibut or seal or seaweed or 2. (Statin$ or reductase inhibitor$).tw. anchov$).tw. 3. (Simvastatin or Atorvastatin or 21. (fish consumption or fish intake or Rosuvastatin or Pravastatin or Lovastatin (fish adj2 diet$)).tw. or Fluvastatin or Mevastatin or 22. or/6-21 Pitavastatin).mp. 23. Bile Acid Sequestrant/ 4. (110862-48-1 or 287714-41-4 or 24. (anticholesteremic resin$ or (bile 75330-75-5 or 79902-63-9 or 81093-37- adj3 resin$) or BAR or BAS or 0 or 93957-54-1).rn. Sequestrant$ or Bile acid$).tw. 5. or/1-4 25. (cholestyramine or colestyramin$ or 6. Omega 3 Fatty Acid/ quantalan or questran or 7. exp Essential Fatty Acid/ colesevelam).tw. 8. exp Unsaturated Fatty Acid/ 26. Cholestyramine/ 9. Fish oils/ 27. Colestipol/ 10. (n 3 fatty acid$ or omega 3).tw. 28. Colestyramine/ 11. eicosapenta?noic.tw,hw,rw. 29. Colestilan/ 12. docosahexa?noic.tw,hw,rw. 30. (colestimide or colestilan or 13. alpha linolenic.tw,hw,rw. colestipol).tw. 14. (linolenate or cervonic or 31. or/23-30 timnodonic).tw,hw,rw. 32. Ezetimibe/ 15. (mediterranean adj diet$).tw. 33. ezetimibe.mp. 16. ((flax or flaxseed or flax seed or 34. 163222-33-1.rn. linseed or rape seed or rapeseed or 35. or/32-34 canola or soy or soybean or walnut or 36. Fibric Acid Derivative/ mustard seed) adj2 oil$).tw. 37. (fibrate$ or fibric acid$).tw. 17. (walnut$ or butternut$ or soybean$ 38. Clofibric acid/ or pumpkin seed$).tw. 39. Clofibrate/ 18. (fish adj2 oil$).tw. 40. Bezafibrate/ 19. (cod liver oil$ or marine oil$ or 41. Gemfibrozil/ marine fat$).tw. 42. Procetofen/ A-3 43. (gemfibrozil or fenofibrate or 73. (walnut$ or butternut$ or soybean$ bezafibrate or clofibrate or clofibric acid or pumpkin seed$).tw. or procetofen or ciprofibrate).tw. 74. (fish adj2 oil$).tw. 44. (637-07-0 or 25812-30-0 or 41859- 75. (cod liver oil$ or marine oil$ or 67-0 or 882-09-7 or 49562-28-9).rn. marine fat$).tw. 45. or/36-44 76. (salmon or mackerel or herring or 46. nicotinic acid/ tuna or halibut or seal or seaweed or 47. niacin.tw. anchov$).tw. 48. or/46-47 77. (fish consumption or fish intake or 49. (Zetia or Lopid or Tricor or Lofibra (fish adj2 diet$)).tw. or Welchol or Colestid or Questran or 78. or/61-77 Prevalite).mp. 79. (anticholesteremic resin$ or (bile 50. Drug Therapy, Combination/ adj3 resin$) or BAR or BAS or 51. (combination adj3 therapy).tw. Sequestrant$ or Bile acid$).tw. 52. add-on therapy.tw. 80. (cholestyramine or colestyramin$ or 53. or/50-52 quantalan or questran or 54. 5 and (or/22,31,35,45,48-49,53) colesevelam).tw. 55. exp Hydroxymethylglutaryl-CoA 81. Cholestyramine/ Reductase Inhibitors/ 82. Colestipol/ 56. Heptanoic Acids/ 83. (colestimide or colestilan or 57. (Statin$ or reductase inhibitor$).tw. colestipol).tw. 58. (Simvastatin or Atorvastatin or 84. or/79-83 Rosuvastatin or Pravastatin or Lovastatin 85. ezetimibe.mp. or Fluvastatin or Mevastatin or 86. 163222-33-1.rn. Pitavastatin).mp. 87. (cholester$ adj3 inhibit$).tw. 59. (110862-48-1 or 287714-41-4 or 88. or/85-87 75330-75-5 or 79902-63-9 or 81093-37- 89. (fibrate$ or fibric acid$).tw. 0 or 93957-54-1).rn. 90. Clofibric acid/ 60. or/55-59 91. Clofibrate/ 61. exp fatty acids, omega-3/ 92. Bezafibrate/ 62. fatty acids, essential/ 93. Gemfibrozil/ 63. Dietary Fats, Unsaturated/ 94. Procetofen/ 64. linolenic acids/ 95. (gemfibrozil or fenofibrate or 65. exp fish oils/ bezafibrate or clofibrate or clofibric acid 66. (n 3 fatty acid$ or omega 3).tw. or procetofen or ciprofibrate).tw. 67.
Load more

Recommended publications
  • No Name of Drug Branded/Generic Drug Class 1 Acipimox Capsule 250Mg Olbetam Nicotinic Acid 1.50 2.14 2 Atorvastatin Calcium 10Mg
    MEDICATIONS FOR TREATMENT OF HIGH BLOOD LIPIDS (HYPERLIPIDEMIA) PRICE RANGE (S$) PER NO NAME OF DRUG BRANDED/GENERIC DRUG CLASS TABLET/ CAPSULE/ SACHET 1 ACIPIMOX CAPSULE 250MG OLBETAM NICOTINIC ACID 1.50 - 2.14 STATIN & CALCIUM 4.40 - 4.90 2 ATORVASTATIN CALCIUM 10MG AMLODIPINE BESYLATE 10MG TABLET CADUET CHANNEL BLOCKERS STATIN & CALCIUM 3.88 - 4.00 3 ATORVASTATIN CALCIUM 10MG AMLODIPINE BESYLATE 5MG TABLET CADUET CHANNEL BLOCKERS STATIN & CALCIUM 4.33 - 4.90 4 ATORVASTATIN CALCIUM 20MG AMLODIPINE BESYLATE 10MG TABLET CADUET CHANNEL BLOCKERS STATIN & CALCIUM 4.05 - 4.80 5 ATORVASTATIN CALCIUM 20MG AMLODIPINE BESYLATE 5MG TABLET CADUET CHANNEL BLOCKERS 6 ATORVASTATIN CALCIUM 10MG LIPITOR STATIN 2.60 - 2.60 7 ATORVASTATIN CALCIUM 20MG LIPITOR STATIN 2.99 - 3.00 8 ATORVASTATIN CALCIUM 40MG LIPITOR STATIN 4.10 - 8.20 9 ATORVASTATIN CALCIUM 80MG LIPITOR STATIN 8.45 - 8.95 10 BEZAFIBRATE SR TABLET 400MG BEZALIP FIBRATES 0.00 - 0.00 11 CHOLESTYRAMINE 4G/SACHET GENERIC FIBRATES 1.35 - 2.25 12 CIPROFIBRATE TABLET 100MG MODALIM FIBRATES 1.60 - 1.75 13 FENOFIBRATE CAPSULE 200MG APO-FENO-MICRO FIBRATES 0.71 - 1.07 14 FENOFIBRATE CAPSULE 200MG LIPANTHYL FIBRATES 1.45 - 1.45 15 FENOFIBRATE CAPSULE 145MG LIPANTHYL PENTA 145 FIBRATES 1.75 - 2.05 16 FENOFIBRATE TABLET 160MG LIPANTHYL SUPRA 160 FIBRATES 1.45 - 1.45 17 FLUVASTATIN SODIUM CAPSULE 20MG LESCOL STATIN 1.85 - 1.86 18 FLUVASTATIN SODIUM CAPSULE 40MG LESCOL STATIN 3.29 - 3.39 19 FLUVASTATIN SODIUM CAPSULE 80MG LESCOL XL STATIN 3.60 - 3.93 20 GEMFIBROZIL CAPSULES 300MG GENERIC-IPOLIPID FIBRATES
    [Show full text]
  • Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?
    Annals of Medicine ISSN: 0785-3890 (Print) 1365-2060 (Online) Journal homepage: http://www.tandfonline.com/loi/iann20 Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes? M. Ruscica, N. Ferri, C. Macchi, A. Corsini & C. R. Sirtori To cite this article: M. Ruscica, N. Ferri, C. Macchi, A. Corsini & C. R. Sirtori (2018): Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?, Annals of Medicine, DOI: 10.1080/07853890.2018.1498118 To link to this article: https://doi.org/10.1080/07853890.2018.1498118 Accepted author version posted online: 06 Jul 2018. Submit your article to this journal View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=iann20 LIPID LOWERING DRUGS AND INFLAMMATORY CHANGES: AN IMPACT ON CARDIOVASCULAR OUTCOMES? M. Ruscica1*, N. Ferri2*, C. Macchi1, A. Corsini1 and C. R. Sirtori3 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy; 2Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova, Italy; 3Centro Dislipidemie, A.S.S.T. Grande Ospedale Metropolitano Niguarda, Milan, Italy *Both authors contributed equally to this work Corresponding Author: Cesare R. Sirtori [email protected] Abstract Inflammatory changes are responsible for maintenance of the atherosclerotic process and may underlie some of the most feared vascular complications. Among the multiple mechanisms of inflammation, the arterial deposition of lipids and particularly of cholesterol crystals is the one responsible for activation of inflammasome NLRP3, followed by the rise of circulating markers, mainly C-reactive protein (CRP). Elevation of lipoproteins, LDL but also VLDL and remnants, associates with increased inflammatory changes and coronary risk.
    [Show full text]
  • Drug Class Review Antianginal Agents
    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
    [Show full text]
  • Effects of a Policosanol Supplement on Serum Lipid Concentrations In
    Downloaded from https://www.cambridge.org/core British Journal of Nutrition (2006), 95, 968–975 DOI: 10.1079/BJN20061715 q The Authors 2006 Effects of a policosanol supplement on serum lipid concentrations in . IP address: hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects 170.106.40.139 A. Greyling, C. De Witt, W. Oosthuizen and J. C. Jerling* , on School of Physiology, Nutrition and Consumer Sciences, North-West University (Potchefstroom Campus), South Africa 25 Sep 2021 at 08:49:47 (Received 28 June 2005 – Revised 28 November 2005 – Accepted 2 December 2005) Policosanol is a mixture of higher aliphatic primary alcohols that is extracted from purified sugar cane wax or a variety of other plant sources, and has been shown to have beneficial effects on serum lipid concentrations. The objective of this study was to investigate the effects of a policosanol , subject to the Cambridge Core terms of use, available at supplement (Octa-60) on lipid profiles of hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Nineteen hypercholes- terolaemic and familial hypercholesterolaemic subjects completed this randomised, placebo-controlled, double-blind study. The subjects received either a daily dose of 20 mg policosanol or placebo for 12 weeks. After a wash-out period of 4 weeks, the interventions were crossed over. Lipid levels were measured at baseline and at the end of each intervention period. No significant differences in total cholesterol and LDL-cholesterol from baseline to end or between policosanol and placebo were seen in the hypercholesterolaemic or familial hypercholesterolaemic groups. There were small reductions in total cholesterol and LDL-cholesterol from baseline to end in the hypercholesterolaemic group, but these changes did not differ significantly from the changes with the placebo, indicating that the observed decrease in cholesterol in the policosanol group was not due to the specific effect of policosanol treatment.
    [Show full text]
  • Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
    nutrients Review Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease Cong Xie 1,† , Weikun Huang 1,2,† , Richard L. Young 1,3 , Karen L. Jones 1,4 , Michael Horowitz 1,4, Christopher K. Rayner 1,5 and Tongzhi Wu 1,4,6,* 1 Adelaide Medical School, Center of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5005, Australia; [email protected] (C.X.); [email protected] (W.H.); [email protected] (R.L.Y.); [email protected] (K.L.J.); [email protected] (M.H.); [email protected] (C.K.R.) 2 The ARC Center of Excellence for Nanoscale BioPhotonics, Institute for Photonics and Advanced Sensing, School of Physical Sciences, The University of Adelaide, Adelaide 5005, Australia 3 Nutrition, Diabetes & Gut Health, Lifelong Health Theme South Australian Health & Medical Research Institute, Adelaide 5005, Australia 4 Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide 5005, Australia 5 Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide 5005, Australia 6 Institute of Diabetes, School of Medicine, Southeast University, Nanjing 210009, China * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Bile acids are cholesterol-derived metabolites with a well-established role in the digestion and absorption of dietary fat. More recently, the discovery of bile acids as natural ligands for the nuclear farnesoid X receptor (FXR) and membrane Takeda G-protein-coupled receptor 5 (TGR5), and Citation: Xie, C.; Huang, W.; Young, the recognition of the effects of FXR and TGR5 signaling have led to a paradigm shift in knowledge R.L.; Jones, K.L.; Horowitz, M.; regarding bile acid physiology and metabolic health.
    [Show full text]
  • SUMMARY of the PRODUCT CHARACTERISTICS 1. NAME of the MEDICINAL PRODUCT <Invented Name> 10 Mg/10 Mg Film-Coated Tablets
    SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Invented name> 10 mg/10 mg film-coated tablets <Invented name> 20 mg/10 mg film-coated tablets <Invented name> 40 mg/10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <Invented name> 10 mg/10 mg: Each film-coated tablet contains 10 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 20 mg/10 mg: Each film-coated tablet contains 20 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. <Invented name> 40 mg/10 mg: Each film-coated tablet contains 40 mg of rosuvastatin (as rosuvastatin calcium) and 10 mg of ezetimibe. Excipient with known effect: <Invented name> 10 mg/10 mg: Each film-coated tablet contains 111.2 mg of lactose (as lactose monohydrate). <Invented name> 20 mg/10 mg: Each film-coated tablet contains 168.6 mg of lactose (as lactose monohydrate). <Invented name> 40 mg/10 mg: Each film-coated tablet contains 286.0 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) <Invented name> 10 mg/10 mg: white to off-white oblong film-coated tablets. <Invented name> 20 mg/10 mg: yellow to light yellow oblong film-coated tablets. <Invented name> 40 mg/10 mg: pink oblong film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH) <Invented name> is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.
    [Show full text]
  • Category Approaches, Read-Across, (Q)SAR Technical Report No
    Category approaches, Read-across, (Q)SAR Technical Report No. 116 EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS Category approaches, Read-across, (Q)SAR Technical Report No. 116 Brussels, November 2012 ISSN-0773-8072-116 (print) ISSN-2079-1526-116 (online) Category approaches, Read-across, (Q)SAR ECETOC Technical Report No. 116 © Copyright – ECETOC AISBL European Centre for Ecotoxicology and Toxicology of Chemicals 2 Avenue E. Van Nieuwenhuyse (Bte 8), B-1160 Brussels, Belgium. All rights reserved. No part of this publication may be reproduced, copied, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder. Applications to reproduce, store, copy or translate should be made to the Secretary General. ECETOC welcomes such applications. Reference to the document, its title and summary may be copied or abstracted in data retrieval systems without subsequent reference. The content of this document has been prepared and reviewed by experts on behalf of ECETOC with all possible care and from the available scientific information. It is provided for information only. ECETOC cannot accept any responsibility or liability and does not provide a warranty for any use or interpretation of the material contained in the publication. ECETOC TR No. 116 Category approaches, Read-across, (Q)SAR Category approaches, Read-across, (Q)SAR TABLE OF CONTENTS SUMMARY 1 1. INTRODUCTION 3 1.1 Terms of reference 4 1.2 Scope 5 1.3 Roadmap of the report 6 2. DEFINITIONS FOR NON-TESTING APPROACHES 8 2.1 Data gap filling 9 2.1.1 Read-across 9 2.1.2 Trend analysis and computational methods based on internal models 13 2.1.3 External (Q)SAR models and expert systems 14 3.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Package Leaflet: Information for the Patient Nustendi 180 Mg/10 Mg Film-Coated Tablet Bempedoic Acid/Ezetimibe This Medicine Is
    Package leaflet: Information for the patient Nustendi 180 mg/10 mg film-coated tablet bempedoic acid/ezetimibe This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Nustendi is and what it is used for 2. What you need to know before you take Nustendi 3. How to take Nustendi 4. Possible side effects 5. How to store Nustendi 6. Contents of the pack and other information 1. What Nustendi is and what it is used for What Nustendi is and how it works Nustendi is a medicine that lowers levels of ‘bad’ cholesterol (also called “LDL-cholesterol”), a type of fat, in the blood. Nustendi contains two active substances, which reduce your cholesterol in two ways: • bempedoic acid decreases the production of cholesterol in the liver and increases the removal of LDL-cholesterol from the blood; • ezetimibe works in your bowel by reducing the amount of cholesterol absorbed from food.
    [Show full text]
  • Bristol-Myers Squibb Company
    Bristol-Myers Squibb Company Rx only COUMADIN TABLETS Anticoagulant (Warfarin Sodium Tablets, USP) Crystalline COUMADIN FOR INJECTION (Warfarin Sodium for Injection, USP) DESCRIPTION COUMADIN (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4- hydroxycoumarin and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. The crystallization of warfarin sodium virtually eliminates trace impurities present in amorphous warfarin. Its empirical formula is C19H15NaO4, and its structural formula may be represented by the following: O O H C ONa CH2COCH3 Crystalline warfarin sodium occurs as a white, odorless, crystalline powder, is discolored by light and is very soluble in water; freely soluble in alcohol; very slightly soluble in chloroform and in ether. COUMADIN Tablets for oral use also contain: All strengths: Lactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake 3 mg: FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 4 mg: FD&C Blue No. 1 Aluminum Lake 5 mg: FD&C Yellow No. 6 Aluminum Lake 1 Approved 1.0 proposed.pdf Page 001 Bristol-Myers Squibb Company 6 mg: FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 1 Aluminum Lake 7-1/2 mg: D&C Yellow No.
    [Show full text]
  • Student Number: 201477310
    COPYRIGHT AND CITATION CONSIDERATIONS FOR THIS THESIS/ DISSERTATION o Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. o NonCommercial — You may not use the material for commercial purposes. o ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. How to cite this thesis Surname, Initial(s). (2012) Title of the thesis or dissertation. PhD. (Chemistry)/ M.Sc. (Physics)/ M.A. (Philosophy)/M.Com. (Finance) etc. [Unpublished]: University of Johannesburg. Retrieved from: https://ujcontent.uj.ac.za/vital/access/manager/Index?site_name=Research%20Output (Accessed: Date). Metabolomics, Physicochemical Properties and Mycotoxin Reduction of Whole Grain Ting (a Southern African fermented food) Produced via Natural and Lactic acid bacteria (LAB) fermentation A Thesis submitted to the Faculty of Science, University of Johannesburg, South Africa In partial fulfilment of the requirement for the award of a Doctoral Degree in Food Technology By OLUWAFEMI AYODEJI ADEBO STUDENT NUMBER: 201477310 Supervisor : Dr. E. Kayitesi Co-supervisor: Prof. P. B. Njobeh October 2018 EXECUTIVE SUMMARY Drought and challenges related to climate change are some of the issues facing sub-Saharan Africa countries, with dire consequences on agriculture and food security. Due to this prevailing situation, drought and climate resistant crops like sorghum (Sorghum bicolor (L) Moench) can adequately contribute to food security. The versatility and importance of sorghum is well reflected in its use as a major food source for millions of people in sub-Saharan Africa.
    [Show full text]